gepotidacin - Drug Hunter
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Antibiotics | Free Full-Text | Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia—An In Vitro and In Vivo Study
Antibiotics | Free Full-Text | Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges
First Novel Antibiotic Since 20 Years, Gepotidacin Debuts To Treat Drug Resistance Urinary Tract Infections (UTIs) Amidst Growing Incidences! - Thailand Medical News
Dose Selection for a Phase 3 Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Gonorrhoea | GSK
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
TITLE PAGE
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants | SpringerLink
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants wi
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea | Sexually Transmitted Infections
Gepotidacin for Urinary Tract Infection Clinical Trial 2023 | Power
TITLE PAGE
Gepotidacin (GSK2140944) | Cas# 1075236-89-3 - GlpBio
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose- Ranging, Single-Oral Dose Eva
With endpoints already met, GSK halts trial into new antibiotic
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose- Ranging, Single-Oral Dose Eva
Gepotidacin (GSK2140944) Demonstrates Similar Safety and Pharmacokinetics in Adults and Adolescents (12 to ˂18 years) | GSK
Dose Selection for a Phase 3 Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Gonorrhoea | GSK
Overview of microbiome dynamics during gepotidacin Phase 2a clinical... | Download Scientific Diagram
